To answer your question, no. Because our stem cell niche degrades over time, we perceive a strong value of banking to come from the delta between when you banked, and when you employ your younger biology in future applications. The current regulatory environment doesn't change that calculus.
Also, we wouldn't want to expand/grow your sample before freezing anyway. The particulars of the expansion itself could change depending on the application, so we want to preserve them in a state that will afford the broadest range of future use.
Regarding the second half, I'll let Mark jump in when he comes back if he wishes. In the lab, he's had over a decade and half to muse about the regulatory environment. I can tell you that as we see it, we're near the cusp of where cellular therapies begin to transition from the clinic to the marketplace.
To answer your question, no. Because our stem cell niche degrades over time, we perceive a strong value of banking to come from the delta between when you banked, and when you employ your younger biology in future applications. The current regulatory environment doesn't change that calculus.
Also, we wouldn't want to expand/grow your sample before freezing anyway. The particulars of the expansion itself could change depending on the application, so we want to preserve them in a state that will afford the broadest range of future use.
Regarding the second half, I'll let Mark jump in when he comes back if he wishes. In the lab, he's had over a decade and half to muse about the regulatory environment. I can tell you that as we see it, we're near the cusp of where cellular therapies begin to transition from the clinic to the marketplace.